Fulton Breakefield Broenniman LLC Sells 821 Shares of Amgen Inc. (NASDAQ:AMGN)

Fulton Breakefield Broenniman LLC trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 10.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,313 shares of the medical research company’s stock after selling 821 shares during the period. Fulton Breakefield Broenniman LLC’s holdings in Amgen were worth $2,106,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. BIP Wealth LLC boosted its stake in shares of Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock worth $360,000 after acquiring an additional 32 shares during the period. Southland Equity Partners LLC boosted its stake in Amgen by 2.3% in the 4th quarter. Southland Equity Partners LLC now owns 1,538 shares of the medical research company’s stock worth $443,000 after purchasing an additional 34 shares during the period. Acropolis Investment Management LLC grew its holdings in Amgen by 3.5% during the 4th quarter. Acropolis Investment Management LLC now owns 999 shares of the medical research company’s stock valued at $288,000 after buying an additional 34 shares in the last quarter. Opal Wealth Advisors LLC raised its position in shares of Amgen by 1.9% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,868 shares of the medical research company’s stock valued at $538,000 after buying an additional 34 shares during the last quarter. Finally, Marino Stram & Associates LLC lifted its holdings in shares of Amgen by 0.7% in the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after buying an additional 34 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

AMGN has been the topic of several recent research reports. Morgan Stanley lowered their target price on Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Raymond James initiated coverage on shares of Amgen in a research note on Thursday, March 28th. They set a “market perform” rating on the stock. UBS Group dropped their price objective on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. TD Cowen reduced their target price on shares of Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $320.00 price target on shares of Amgen in a report on Friday, April 12th. Ten equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $296.95.

Amgen Stock Up 0.2 %

AMGN stock opened at $269.98 on Friday. Amgen Inc. has a one year low of $211.71 and a one year high of $329.72. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65. The firm’s fifty day moving average is $275.10 and its 200 day moving average is $281.52. The firm has a market cap of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.61 and a beta of 0.58.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the firm earned $4.09 EPS. On average, research analysts forecast that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.33%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.